Uterine leiomyomata are among the most frequently diagnosed neoplasms among women. Although benign, these tumors represent a major source of morbidity among women of reproductive age, as they are the primary indication for nearly 200, 000 hysterectomies annually in the United States. Little is known or has been studied regarding the etiology or epidemiology of uterine leiomyomata. Accumulating clinical and laboratory evidence suggests and a major factor in the development of these neoplasms, as with endometrial carcinoma, is exposure of a woman to excess or """"""""unopposed"""""""" estrogens. An important prediction of this hypothesis is that use of combined oral contraceptives should reduce the risk of these neoplasms. A population- based case-control study is proposed to determine hormonal and hormonally- mediated factors that may predispose a woman to develop uterine leiomyomata, with particular emphasis on the role of combined oral contraceptive agents. The setting is Group Health Cooperative (GHC) of Puget Sound, a large clinic and hospital-based pre-paid health plan serving approximately 370,000 persons. Eight hundred female enrollees 25 to 59 years of age who receive a first diagnosis of uterine leiomyomata as confirmed by surgery or ultrasound between September 1, 1995 and August 31, 1998 will be included as cases in the study, for comparison, 800 women similar in age, length of enrollment, and primary care clinic will be selected at random from computerized membership files and health care utilization files and recruited as controls. Both groups will be interviewed in-person regarding use of oral contraceptives, as well as other factors known or suspected to influence the exposure to excess estrogens (e.g. use of post-menopausal estrogens and progestogens, obesity, cigarette smoking, reproductive history). For each case and control, independent classification of use of oral contraceptives and other hormonal medications will be obtained through linkage to the GHC computerized pharmacy database. In a randam sample of 400 controls, trans-vaginal ultrasound exams will be performed to measure the prevalence of undetected leiomyomata. Analyses comparing cases and controls with respect to oral contraceptive use and other factors will be conducted to address the specific aims.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
5R01HD029819-03
Application #
2403287
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Project Start
1995-09-01
Project End
1999-08-31
Budget Start
1997-09-01
Budget End
1998-08-31
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Atkinson, Charlotte; Lampe, Johanna W; Scholes, Delia et al. (2006) Lignan and isoflavone excretion in relation to uterine fibroids: a case-control study of young to middle-aged women in the United States. Am J Clin Nutr 84:587-93
Reed, Susan D; Cushing-Haugen, Kara L; Daling, Janet R et al. (2004) Postmenopausal estrogen and progestogen therapy and the risk of uterine leiomyomas. Menopause 11:214-22
Atkinson, Charlotte; Skor, Heather E; Fitzgibbons, E Dawn et al. (2002) Overnight urinary isoflavone excretion in a population of women living in the United States, and its relationship to isoflavone intake. Cancer Epidemiol Biomarkers Prev 11:253-60
Schwartz, S M (2001) Invited commentary: Studying the epidemiology of uterine leiomyomata--past, present, and future. Am J Epidemiol 153:27-9; discussion 30
Schwartz, S M (2001) Epidemiology of uterine leiomyomata. Clin Obstet Gynecol 44:316-26
Schwartz, S M; Marshall, L M; Baird, D D (2000) Epidemiologic contributions to understanding the etiology of uterine leiomyomata. Environ Health Perspect 108 Suppl 5:821-7